Emma Guttman-Yassky, MD, PhD The National Alopecia Areata Foundation applauds the announcement that the National Institutes of Health (NIH) has awarded a $6.6 million grant to Mount Sinai Health System to support its investigation of dupilumab as a treatment for children with alopecia areata. This research, led by Emma Guttman-Yassky, MD, PhD, the Waldman Professor and Chair of Dermatology at the Icahn School of Medicine and Mount Sinai Health System, will explore the use of dupilumab, a monoclonal antibody with a strong efficacy and safety profile that is approved for a number of diseases, including atopic dermatitis (i.e. eczema) and asthma. Dr. Guttman was encouraged by a recent clinical trial of adult alopecia patients with severe hair loss showing that dupilumab induced significant hair regrowth. Her investigation will explore dupilumab as a treatment for alopecia areata in pediatric patients with a history of atopic (allergic) diseases. “We are extremely pleased to see the NIH commit this significant funding for alopecia areata research,” said Nicole Friedland, NAAF President & CEO. “We wish to congratulate the team at Mount Sinai and express gratitude to the NIH. We hope to see many more NIH grants for alopecia areata research as we seek more treatments and deeper understanding of this autoimmune disease.” Learn more: Register here for NAAF’s upcoming webinar on July 17, 2024, with Dr. Emma Guttman and Dr. Benjamin Ungar on this research. Watch a CBS News story on Dr. Guttman’s research. Clinical trial information
